A critical issue facing biobanks is how to handle requests for access so as to ensure fair and equitable access for researchers, whilst maintaining some of the resource for potential future use. Which of the following parameters is NOT one the Ebola biobank should consider when developing its biospecimen access policy? a. Who can access and use the biospecimens and data for research b. How the biobank will prioritize multiple access requests c. Will there be any utilization restrictions on the biospecimens, for example no use in genetic studies d. Who will maintain intellectual property rights on research performed using the biospecimens from the Ebola outbreak e. Which member of the biospecimen access committee will receive authorship on papers utilizing biospecimens from the Ebola biobank